Photobiology Unit, Dermatology Centre, The University of Manchester & Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, U.K.
Stirling Community Hospital, Stirling, U.K.
Br J Dermatol. 2018 Dec;179(6):1277-1296. doi: 10.1111/bjd.16838. Epub 2018 Sep 9.
Topical photodynamic therapy (PDT) is an established treatment option for low-risk basal cell carcinoma (BCC).
To compare efficacy, cosmesis and tolerability of PDT for BCC with alternative treatments.
MEDLINE, PubMed, Embase and CENTRAL databases were searched from inception until 1 September 2017. Included studies were randomized controlled trials (RCTs) of PDT for nodular (n) and superficial (s) BCC reporting at least one of the following outcomes: clearance at 3 months and sustained at 1 or 5 years; recurrence at ≥ 1 year; cosmesis; adverse events; tolerability.
From 2331 search results, 15 RCTs (2327 patients; 3509 BCCs) were included. PDT efficacy (5-year sustained clearance) was high but inferior to excisional surgery [nBCC pooled risk ratio (RR) 0·76; 95% confidence interval (CI) 0·63-0·91], and without re-treatment of partially responding lesions, was modestly inferior to imiquimod (sBCC: RR 0·81; 95% CI 0·70-0·95) and similar to fluorouracil (sBCC: RR 0·88; 95% CI 0·75-1·04). Five-year sustained clearance was inferior with conventional vs. fractionated PDT (sBCC: RR 0·76; 95% CI 0·68-0·84). PDT cosmesis was superior to surgery (sBCC: RR 1·68, 95% CI 1·32-2·14; nBCC: RR 1·82, 95% CI 1·19-2·80) and cryosurgery (BCC: RR 3·73, 95% CI 1·96-7·07), and without re-treatment of partially responding lesions was similar to imiquimod (sBCC: RR 1·01, 95% CI 0·85-1·19) and fluorouracil (sBCC: RR 1·04, 95% CI 0·88-1·24). Peak pain was higher but of shorter duration with PDT than topical treatments. Serious adverse reactions were rarer with PDT than imiquimod (sBCC: RR 0·05, 95% CI 0·00-0·84) and fluorouracil (sBCC: RR 0·11, 95% CI 0·01-2·04). Combination PDT regimens demonstrated reduced recurrence and improved cosmesis; however, results from these small studies were often nonsignificant.
PDT is an effective treatment for low-risk BCC, with excellent cosmesis and safety. Imiquimod has higher efficacy than single-cycle PDT but more adverse effects. Highest efficacy is with excisional surgery. Fractionated and combination PDT options warrant further study.
局部光动力疗法(PDT)是治疗低危基底细胞癌(BCC)的一种既定治疗选择。
比较 PDT 治疗结节性(n)和浅表性(s)BCC 的疗效、美容效果和耐受性,与替代疗法相比。
从数据库建立到 2017 年 9 月 1 日,检索 MEDLINE、PubMed、Embase 和 CENTRAL 数据库。纳入的研究是随机对照试验(RCT),用于 PDT 治疗结节性(n)和浅表性(s)BCC,至少报告以下结果之一:3 个月时清除,1 年或 5 年时持续清除;≥1 年时复发;美容效果;不良反应;耐受性。
从 2331 条检索结果中,纳入了 15 项 RCT(2327 名患者;3509 个 BCC)。PDT 疗效(5 年持续清除率)较高,但低于切除术[nBCC 汇总风险比(RR)0.76;95%置信区间(CI)0.63-0.91],且不包括部分反应病变的再治疗,略低于咪喹莫特(sBCC:RR 0.81;95% CI 0.70-0.95),与氟尿嘧啶(sBCC:RR 0.88;95% CI 0.75-1.04)相似。与常规 PDT 相比,5 年持续清除率较低,PDT 为常规 PDT(sBCC:RR 0.76;95% CI 0.68-0.84)。与手术(sBCC:RR 1.68,95% CI 1.32-2.14;nBCC:RR 1.82,95% CI 1.19-2.80)和冷冻疗法(BCC:RR 3.73,95% CI 1.96-7.07)相比,PDT 的美容效果更好,且不包括部分反应病变的再治疗,与咪喹莫特(sBCC:RR 1.01,95% CI 0.85-1.19)和氟尿嘧啶(sBCC:RR 1.04,95% CI 0.88-1.24)相似。与局部治疗相比,PDT 引起的峰值疼痛较高,但疼痛持续时间较短。与咪喹莫特(sBCC:RR 0.05,95% CI 0.00-0.84)和氟尿嘧啶(sBCC:RR 0.11,95% CI 0.01-2.04)相比,PDT 的严重不良反应较少。
PDT 是治疗低危 BCC 的有效方法,具有良好的美容效果和安全性。咪喹莫特的疗效高于单周期 PDT,但不良反应更多。最高疗效是手术切除。分阶段和联合 PDT 方案值得进一步研究。